Interleukin-5 Receptor alpha-directed Cytolytic Antibody class drugs

1 result
AstraZeneca Pharmaceuticals LP
Usage: FASENRA is indicated for add-on maintenance treatment of severe asthma in patients aged 6 and older with an eosinophilic phenotype, and for adults with eosinophilic granulomatosis with polyangiitis (EGPA). It is not for acute bronchospasm relief.